PrecisionLife and Ovation collaborate to identify biomarkers that inform value-based reimbursement for GLP-1 therapies

PrecisionLife and Ovation have partnered to analyze multiomic and clinical data to identify biomarkers that may help predict patient response to GLP-1 receptor agonists, with the aim of informing future value-based reimbursement approaches. 

Rising use of GLP-1 therapies has heightened interest in understanding variations in safety, efficacy, and tolerability. Goldman Sachs Research estimates that the global obesity market for GLP-1s could reach $95 billion by 2030, with 30–70 million annual prescriptions expected in the US alone by the end of the decade. As demand rises, payors face pressure to manage costs while ensuring appropriate access. 

The collaboration will combine Ovation’s longitudinal multiomic and clinical dataset from 25,000 US patients treated with GLP-1 therapies with PrecisionLife’s AI-enabled combinatorial analytics platform. By integrating these datasets, the companies aim to generate insights into the biological mechanisms that may explain differences in patient response. 

According to the announcement, the resulting insights may support development of a test intended to assist payors in determining where GLP-1 therapy use is clinically appropriate and economically justified. The companies note that the goal is to help health systems “achieve the best, most cost-effective outcomes for patients using GLP-1s,” particularly as utilization continues to rise. 

Curt Medeiros, Chief Executive Officer of Ovation, stated: 

"By combining Ovation's best-in-class longitudinal omics and clinical data generation capabilities with PrecisionLife's world-leading analytics, we aim to build the real-world evidence needed to guide payors toward smarter reimbursement policies that improve patient outcomes while controlling cost. Importantly, our biobank, which is representative of both sex and ethnicity in the US, is scaling in complex, chronic diseases at unprecedented speed." 

The findings are expected to support development of a Mechanostic® test designed to link treatment decisions to underlying biological mechanisms. This type of mechanism-based approach may contribute to the design of value-based reimbursement frameworks that better align payment with real-world outcomes. 

Steve Gardner, Chief Executive Officer of PrecisionLife, highlighted that: 

“GLP-1s present both a tremendous preventative health opportunity across multiple indications and a major challenge for health systems and payors. By understanding why some patients respond well and others do not, we can enable payors to make more informed, sustainable coverage decisions, help pharma bring new products to market, and ultimately deliver better value for patients, providers, and the industry."